Discovery and development of ADCs: obstacles and opportunities
Here we have provided historical perspectives on the development of ADCs and highlighted
the obstacles encountered during the development of different ADC generations, which …
the obstacles encountered during the development of different ADC generations, which …
[HTML][HTML] Recent developments in ADC technology: preclinical studies signal future clinical trends
PM Drake, D Rabuka - BioDrugs, 2017 - Springer
The antibody–drug conjugate (ADC) field is in a transitional period. Older approaches to
conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but …
conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but …
ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies
N Amani, FA Dorkoosh, H Mobedi - Current Drug Delivery, 2020 - ingentaconnect.com
Antibody drug conjugates (ADCs), as potent pharmaceutical trojan horses for cancer
treatment, provide superior efficacy and specific targeting along with low risk of adverse …
treatment, provide superior efficacy and specific targeting along with low risk of adverse …
[HTML][HTML] Mechanisms of ADC toxicity and strategies to increase ADC tolerability
TD Nguyen, BM Bordeau, JP Balthasar - Cancers, 2023 - mdpi.com
Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …
[HTML][HTML] A cell-level systems PK-PD model to characterize in vivo efficacy of ADCs
Here, we have presented the development of a systems pharmacokinetics-
pharmacodynamics (PK-PD) model for antibody-drug conjugates (ADCs), which uses …
pharmacodynamics (PK-PD) model for antibody-drug conjugates (ADCs), which uses …
Relationship between in vivo antitumor activity of ADC and payload release in preclinical models
F Li, X Zhang, K Emmerton, M Jonas, J Setter, B Arthur… - Cancer Research, 2014 - AACR
Antibody-drug conjugates (ADC) deliver cytotoxic payloads to target cells via receptor-
mediated internalization. We have demonstrated that SGN-35 (cAC10-vcMMAE) binds to …
mediated internalization. We have demonstrated that SGN-35 (cAC10-vcMMAE) binds to …
Next horizons: ADCs beyond oncology
S Yu, A Lim, MS Tremblay - Innovations for Next-Generation Antibody-Drug …, 2018 - Springer
Most ADCs developed thus far have been explored for oncology indications. Emerging ADC
technologies present many opportunities to apply the modality beyond oncology. The key …
technologies present many opportunities to apply the modality beyond oncology. The key …
[HTML][HTML] The analysis of key factors related to ADCs structural design
H Tang, Y Liu, Z Yu, M Sun, L Lin, W Liu… - Frontiers in …, 2019 - frontiersin.org
Antibody–drug conjugates (ADCs) have developed rapidly in recent decades. However, it is
complicated to map out a perfect ADC that requires optimization of multiple parameters …
complicated to map out a perfect ADC that requires optimization of multiple parameters …
Pushing the envelope: Advancement of ADCs outside of oncology
MJ McPherson, AD Hobson - Antibody-Drug Conjugates: Methods and …, 2020 - Springer
The majority of ADCs in preclinical and clinical development are for oncology indications
where cytotoxic payloads are targeted to antigen-expressing cancer cells. However, the …
where cytotoxic payloads are targeted to antigen-expressing cancer cells. However, the …
Development of anti-cancer ADCs with Concortis' C-and K-lock technology
G Chen, T Zhu, D Deng, H Zhang, D Miao - Cancer Research, 2015 - AACR
Abstract Antibody-Drug Conjugation (ADC) is a rapidly growing area and has been widely
explored for cancer therapy. In the past decade, numerous progresses have been reported …
explored for cancer therapy. In the past decade, numerous progresses have been reported …